Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Viral hepatitis
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the...
Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval
China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving...
Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...
Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property...
Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...
SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024
SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies,...
Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
Beijing-based biotech company Huahui Health, specializing in viral hepatitis, hepatology, and oncology, has announced that...
Xi’an Xintong Pharma’s Pradefavir Wins NMPA Nod for Chronic Hepatitis B Treatment
The National Medical Products Administration (NMPA) has granted market approval for pradefavir, a Category 1...
Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities
Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...
Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...
Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy
Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China
AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...
Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval
Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...